Clinicopathological analysis of oral plasmablastic lymphoma: A systematic review

Rodrigues-Fernandes, Carla Isabelly; Souza, Lucas Lacerda de; Santos-Costa, Sara Ferreira Dos; Silva, André Myller Barbosa; Pontes, Hélder Antônio Rebelo; Lopes, Márcio Ajudarte; Almeida, Oslei Paes de; Brennan, Peter A.; Fonseca, Felipe Paiva

doi:10.1111/jop.12753

Cited by 25 publications

(41 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Different from the low survival rate observed in other high‐grade lymphomas like PBL, we observed a much higher rate for oral DLBCL NOS. Similarly, Rayess et al also observed an overall 5‐year survival of 84% for oropharyngeal DLBCL, whereas a study with 48 oral DLBCL NOS reported a lower 5‐year survival rate of 45% …”

Section: Discussioncontrasting

confidence: 99%

“…In contrast to PBL, 19 Histologically, DLBCL NOS exhibits a mixture of centroblasts and immunoblasts that grow in a diffuse pattern, partially or totally effacing the architecture of the affected organ. 11,17 Immunohistochemically, neoplastic cells express pan B-cell markers, such as CD19, CD20, and PAX5 and are negative for pan T-cell markers.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological analysis of oral diffuse large B‐cell lymphoma, NOS: A systematic review

Rodrigues-Fernandes

Souza

Santos-Costa

et al. 2018

J Oral Pathology Medicine

Self Cite

View full text Add to dashboard Cite

Background Diffuse large B‐cell lymphoma, NOS (DLBCL NOS) is the commonest extranodal non‐Hodgkin lymphoma diagnosed in the oral and maxillofacial region. However, few studies are currently available and its prognostic determinants remain undefined. Purpose To analyse the available data on oral DLBCL NOS and to describe its clinicopathological features, identifying potential prognostic factors. Methods An electronic systematic search was performed using multiple databases with a specific search strategy in April 2018. All reports describing DLBCL NOS involving the oral cavity and jaw bones with sufficient clinicopathological information were assessed. Results Sixty‐three publications were included in the study, comprising 122 cases. Oral DLBCL NOS was found predominantly in elderly males (61.5%), and most often presented as an asymptomatic swelling of the gingiva. Patients commonly were HIV‐negative (36.1%), with few reports describing EBV‐positive cases (four cases/3.3%). Only eight cases presented B symptoms and most cases were classified as stage I or II (48.4%). CHOP therapy was the main treatment option (24.5%) and the overall 5‐year survival rate achieved 83%. Males and advanced Ann Arbor stage patients presented significantly lower survival rates in the univariate analysis, but no significance was found in the multivariate model. Conclusion Oral DLBCL NOS is an aggressive malignancy, but with a high survival rate.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Clinicopathological analysis of oral diffuse large B‐cell lymphoma, NOS: A systematic review

Rodrigues-Fernandes

Souza

Santos-Costa

et al. 2018

J Oral Pathology Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Plasmablastic lymphoma (PBL) is a rare subtype of non-Hodgkin's lymphoma (NHL) (1), which generally presents an aggressive clinical course and low survival rates (2). The etiology of PBL is not clear, but the importance of the Epstein-Barr virus (EBV) was frequently speculated, since it was detected in 78% of the cases (2). It is well known that the nature of this malignancy, that is, the rapid appearance of the disease, the aggressive invasion in extranodal sites and the frequent repetition, even after remission, make its prognosis extremely poor (1).…”

Section: Introductionmentioning

confidence: 99%

“…Confluent areas of necrosis are also occasionally present (3). The characteristic immunophenotype seen in PBL includes the expression of plasmacytic differentiation markers including CD138, CD38, IRF4 / MUM1 (1,3), the little to no expression of leukocyte common antigen CD45 or the B -Cell Markers CD20, CD 79a, and PAX5 (2,7,8). The most common cytogenetic abnormality observed in PBL is the reorganization of the MYC gene in 8q24, and the immunoglobulin genes act as the most frequent translocation partners (3).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasmablastic lymphoma as a manifestation of the human immunodeficiency virus: Case report

Vera

Córdova

Sepulveda³

et al. 2020

J Clin Exp Dent

View full text Add to dashboard Cite

show abstract

Survival analysis in treated plasmablastic lymphoma patients: a population‐based study

2020

View full text Add to dashboard Cite

Herein we analyzed survival outcomes in chemotherapy-treated patients with plasmablastic lymphoma (PBL) diagnosed between 2010 to 2016 (n = 248). Data was acquired from the Surveillance, Epidemiology, and End Results (SEER) 18 registries database (April 2019 release based on November 2018 submission). The majority of patients were male (81.9%) and younger than 60 years (71.0%). Oral and gastrointestinal (GI) sites were the most frequent primary extranodal locations (23% and 19.4%, respectively). Oral primary location was inversely associated with presence of B symptoms and advanced Ann-Arbor stage. The 3-year and 5-year overall survival (OS) rates of treated PBL patients were 54% (95% CI: 46.5%-60.8%) and 52.8% (95% CI: 45.2%-59.8%). Three-year conditional survival for 2-year and 3-year survivors were 90.3% and 97.8%, overlapping the survival of a general population matched by age, sex and calendar year. In a multivariable analysis, oral primary location was associated with not only better OS (HR 0.43; 95% CI: 0.21-0.88, P = .021) but also better lymphoma-specific survival (LSS) (SHR 0.36; 95% CI: 0.15-0.86, P = .022); age ≥60 years was associated with shorter LSS (SHR 1.73; 95% CI: 1.02-2.96, P = .043). Seven registries granted access to HIV status (n = 93) where HIV infection was detected in 52.7% of cases. The HIV status did not affect survival outcomes in unadjusted and adjusted analyses. We identified clinical characteristics associated with survival and showed that treated PBL patients may achieve long-term survival. 1 | INTRODUCTION Plasmablastic lymphoma (PBL) is a rare aggressive non-Hodgkin lymphoma with unknown incidence. Plasmablastic lymphoma was first described as a distinct clinicopathological entity in 1997 by Delecluse et al. and was shown to be associated with HIV infection (15 of 16 cases), Epstein-Barr virus (EBV) infection (9 of 16 cases) and a predilection for oral cavity, particularly jaw mucosa. 1 Subsequently, PBL was described in non-HIV patients with primary involvement outside of the oral cavity and was incorporated as a distinct clinical lymphoma type into the latest World Health Organization lymphoma classification. 2 It is considered to be a subtype of large B-cell lymphoma with plasmablastic morphology and expression of plasma cell markers (CD79a, CD38, CD138 and MUM-1), but lacking expression of B-cell markers (CD20, PAX-5). 3 The differential diagnosis includes immunoblastic diffuse large B-cell lymphoma, ALK positive diffuse large B-cell lymphoma, HHV-8 positive large B-cell lymphoma, primary effusion lymphoma, plasmablastic or anaplastic multiple myeloma and undifferentiated carcinoma. 3-5 Nodal involvement and association with HIV and EBV are typical for PBL but not seen in plasma cell neoplasms. 5-7 Plasmablastic lymphoma is an aggressive lymphoma with overall survival (OS) ranging from 7 to 62 months, according to small Jorge A. Florindez and Juan Pablo Alderuccio contributed equally to this study.

show abstract

Clinicopathological analysis of oral plasmablastic lymphoma: A systematic review

Abstract: Oral PBL is an aggressive neoplasm with low survival rates, which is influenced by the presence of EBV, presence of B-symptoms, and with the use of chemotherapy only.

Cited by 25 publications

References 32 publications

Clinicopathological analysis of oral diffuse large B‐cell lymphoma, NOS: A systematic review

Clinicopathological analysis of oral diffuse large B‐cell lymphoma, NOS: A systematic review

Plasmablastic lymphoma as a manifestation of the human immunodeficiency virus: Case report

Survival analysis in treated plasmablastic lymphoma patients: a population‐based study

Contact Info

Product

Resources

About